Michael McCaughan
The donut hole inside the Medicare prescription drug benefit is starting to give the
Plugging the Hole in Part D: CMS Tries to Sweeten the Deal for Enhanced Medicare Drug Coverage
The federal Medicare agency is desperate to woo Part D plans to provide brand name drug coverage in the "donut hole" for 2008 despite the catastrophic failure of enhanced plans so far. Manufacturers should root for CMS to make it happen-but prepare for the fallout if the agency can't.
More from Market Access
More from Pink Sheet
• By
The use of J&J’s Darzalex Faspro in high-risk smoldering multiple myeloma could result in overtreatment, but the FDA committee voted in favor of the new claim for delay in development of multiple myeloma.
• By
The glofitamab trial results are not generalizable due to the small number of enrolled US lymphoma patients and adverse results across multiple endpoints for patients from non-Asian regions, the Oncologic Drugs Advisory Committee said.
• By
The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.